Skip to main content
. 2022 May 27;12(6):754. doi: 10.3390/biom12060754

Figure 6.

Figure 6

Chronic lymphocytic leukemia (CLL) unconventional immune cell scenario. NK: NKs are augmented but with less toxicity. Soluble BAG6 (i.e., NKp30-ligand) can stimulate NK cells via NKp30. ILC: ILCs are augmented. γδT: the increase in Vγ9Vδ2 tumor-infiltrating T cells was correlated with a favorable prognosis in CLL. Vδ1 cells that present NCRs could kill CLL cells via NKp30 and NKp44.